KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Current Liabilities (2016 - 2025)

Regeneron Pharmaceuticals has reported Total Current Liabilities over the past 17 years, most recently at $4.4 billion for Q4 2025.

  • Quarterly results put Total Current Liabilities at $4.4 billion for Q4 2025, up 10.75% from a year ago — trailing twelve months through Dec 2025 was $4.4 billion (up 10.75% YoY), and the annual figure for FY2025 was $4.4 billion, up 10.75%.
  • Total Current Liabilities for Q4 2025 was $4.4 billion at Regeneron Pharmaceuticals, down from $4.4 billion in the prior quarter.
  • Over the last five years, Total Current Liabilities for REGN hit a ceiling of $4.4 billion in Q3 2025 and a floor of $2.9 billion in Q3 2022.
  • Median Total Current Liabilities over the past 5 years was $3.6 billion (2024), compared with a mean of $3.5 billion.
  • Biggest five-year swings in Total Current Liabilities: soared 58.9% in 2021 and later decreased 22.49% in 2022.
  • Regeneron Pharmaceuticals' Total Current Liabilities stood at $3.9 billion in 2021, then dropped by 20.12% to $3.1 billion in 2022, then increased by 8.98% to $3.4 billion in 2023, then rose by 15.22% to $3.9 billion in 2024, then rose by 10.75% to $4.4 billion in 2025.
  • The last three reported values for Total Current Liabilities were $4.4 billion (Q4 2025), $4.4 billion (Q3 2025), and $3.7 billion (Q2 2025) per Business Quant data.